• Key Intrahepatic cholangiocarcinoma pipeline therapies in various stages of development include Zanidatamab, Derazantinib, MIV-818, Bemarituzumab, KIN-3248, TYRA-200, Nelitolimod, and others.

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However, the ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Recent developments in the biliary tumor drug landscape have substantially expanded treatment options. In May 2024, AstraZeneca initiated Phase III clinical trials for Rilvegostomig, a promising ...

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers—including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers.

The presence of FGFR2 alterations occurs almost exclusively in intrahepatic cholangiocarcinoma (iCCA) and is seen in 10% to 16% of patients. A question examined in abstracts over the past year has ...

Short Communication Published: 21 May 2007 Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia ...

FGFR2 fusions or rearrangements occur almost exclusively in iCCA, where they are observed in 10-16 percent of patients 5,6,7. About FIGHT-202 ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation ...

TOKYO, Sept 24, 2024--- Anticancer Agent "Tasfygo (R) Tablets 35 mg" Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements. Eisai Co., Ltd. announced today that it ...